RS63989B1 - Postupak evaluacije rizika za pml - Google Patents

Postupak evaluacije rizika za pml

Info

Publication number
RS63989B1
RS63989B1 RS20230142A RSP20230142A RS63989B1 RS 63989 B1 RS63989 B1 RS 63989B1 RS 20230142 A RS20230142 A RS 20230142A RS P20230142 A RSP20230142 A RS P20230142A RS 63989 B1 RS63989 B1 RS 63989B1
Authority
RS
Serbia
Prior art keywords
patient
jcv
pml
therapy
vla
Prior art date
Application number
RS20230142A
Other languages
English (en)
Serbian (sr)
Inventor
Meena Subramanyam
Tatiana Plavina
Gary Lewis Bloomgren
Carmen Bozic
Sophia Lee
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47260338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS63989(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of RS63989B1 publication Critical patent/RS63989B1/sr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Exhaust Gas After Treatment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
RS20230142A 2011-05-31 2012-05-31 Postupak evaluacije rizika za pml RS63989B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161491810P 2011-05-31 2011-05-31
US201161508584P 2011-07-15 2011-07-15
US201161550257P 2011-10-21 2011-10-21
US201261636588P 2012-04-20 2012-04-20
EP19169482.7A EP3575792B1 (en) 2011-05-31 2012-05-31 Method of assessing risk of pml

Publications (1)

Publication Number Publication Date
RS63989B1 true RS63989B1 (sr) 2023-03-31

Family

ID=47260338

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20190690A RS58967B1 (sr) 2011-05-31 2012-05-31 Metod evaluacije rizika za pml
RS20230142A RS63989B1 (sr) 2011-05-31 2012-05-31 Postupak evaluacije rizika za pml

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20190690A RS58967B1 (sr) 2011-05-31 2012-05-31 Metod evaluacije rizika za pml

Country Status (20)

Country Link
US (3) US12105090B2 (enExample)
EP (3) EP4187248A1 (enExample)
JP (5) JP6243838B2 (enExample)
KR (3) KR102473834B1 (enExample)
CN (1) CN103635803A (enExample)
AU (1) AU2012262122B2 (enExample)
CA (1) CA2836490A1 (enExample)
CY (1) CY1121981T1 (enExample)
DK (2) DK2715352T3 (enExample)
ES (2) ES2729945T3 (enExample)
FI (1) FI3575792T3 (enExample)
HR (2) HRP20190860T1 (enExample)
HU (2) HUE043339T2 (enExample)
LT (2) LT2715352T (enExample)
PL (2) PL2715352T3 (enExample)
PT (2) PT3575792T (enExample)
RS (2) RS58967B1 (enExample)
SI (2) SI3575792T1 (enExample)
SM (2) SMT202300060T1 (enExample)
WO (1) WO2012166971A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
BRPI0708392A2 (pt) 2006-03-03 2011-05-24 Elan Pharm Inc métodos de tratamento de um paciente com uma doença inflamatória ou autoimune com natalizumab e de uso de natalizumab para tratar um paciente com uma doença inflamatória ou autoimune
ES2666372T3 (es) 2009-10-11 2018-05-04 Biogen Ma Inc. Ensayos relacionados con anti-VLA-4
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
EP4524571A3 (en) 2010-01-11 2025-06-11 Biogen MA Inc. Assay for jc virus antibodies
KR102473834B1 (ko) 2011-05-31 2022-12-02 바이오젠 엠에이 인코포레이티드 Pml의 위험을 판단하는 방법
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法
US20160223565A1 (en) * 2013-09-18 2016-08-04 The Johns Hopkins University Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk
ES2818823T3 (es) 2014-02-27 2021-04-14 Biogen Ma Inc Método de evaluación del riesgo de LMP
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
AU2018355447A1 (en) 2017-10-26 2020-05-21 Biogen Ma Inc. Extended interval dosing of natalizumab
MX2023005596A (es) 2020-11-14 2023-08-15 Biogen Ma Inc Regímenes de dosificación bifásica subcutánea para anticuerpos anti-vla-4.
JP2024513974A (ja) 2021-04-13 2024-03-27 バイオジェン・エムエイ・インコーポレイテッド 慢性活動性白質病変／放射線学的孤立性症候群を治療するための組成物及び方法

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
DE69229334T2 (de) 1991-01-11 1999-12-16 Quidel Corp., San Diego Einstufiges querfluss analysenverfahren und ein darin verwendeter nichtsaugfähiger träger
US5213796A (en) 1991-05-06 1993-05-25 Dana Farber Cancer Institute Assay for polyomavirus in humans and uses thereof
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
JPH07503543A (ja) 1992-02-04 1995-04-13 クイデル　コーポレイション 乾燥試薬を用いる細菌抗原の簡易化抽出法
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
WO1993018398A1 (en) 1992-03-10 1993-09-16 Quidel Corporation Red blood cell separation means for specific binding assays
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
DE50001665D1 (de) 1999-10-12 2003-05-08 Connex Ges Zur Optimierung Von Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
WO2001043774A1 (en) 1999-12-16 2001-06-21 Biogen, Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
WO2001055112A1 (en) 2000-01-27 2001-08-02 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
AU4465001A (en) 2000-03-30 2001-10-15 Nippon Kayaku Kabushiki Kaisha Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
AU1038402A (en) 2000-10-17 2002-04-29 Besst Test Aps Assay for directly detecting a rs virus related biological cell in a body fluid sample
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
EP1419387B1 (en) 2001-08-20 2012-01-04 Proteome Systems Ltd. Diagnostic testing process
WO2003016902A1 (en) 2001-08-20 2003-02-27 Proteome Systems Intellectual Property Pty Ltd Diagnostic testing process and apparatus
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
ATE374944T1 (de) * 2001-12-03 2007-10-15 Abgenix Inc Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
US8478604B2 (en) 2002-06-21 2013-07-02 Mckesson Technologies Inc. Closed loop medication use system and method
WO2005052567A1 (en) 2003-11-24 2005-06-09 Biogen Idec Ma Inc. Methods for detecting half-antibodies using chip-based gel electrophoresis
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
EP2298356A3 (en) 2004-07-08 2011-08-10 Elan Pharmaceuticals, Inc. Multivalent VLA-4 antagonists comprising polymer moieties
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1833509A4 (en) 2004-12-03 2008-12-03 Biogen Idec Inc DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
US7972775B2 (en) * 2005-03-03 2011-07-05 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing Natalizumab treatment
RS56418B2 (sr) 2005-04-04 2025-01-31 Biogen Ma Inc Metodi evaluacije imunskog odgovora na terapijsko sredstvo
JP2009500040A (ja) * 2005-07-08 2009-01-08 フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン・デイー／ビー／エイ ドレクセルユニバーシテイカレツジオブメデイシン ニューロンの神経炎症的破壊をモニタリングする方法およびホスホリパーゼａ２に関連する炎症性成分を有する疾患を処置する方法
JP5101512B2 (ja) 2005-09-29 2012-12-19 エラン ファーマシューティカルズ，インコーポレイテッド Ｖｌａ−４によって媒介される白血球接着を阻害するピリミジニルアミド化合物
NZ570679A (en) 2006-02-27 2011-01-28 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated By VLA-4
CA2641160A1 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
BRPI0708392A2 (pt) 2006-03-03 2011-05-24 Elan Pharm Inc métodos de tratamento de um paciente com uma doença inflamatória ou autoimune com natalizumab e de uso de natalizumab para tratar um paciente com uma doença inflamatória ou autoimune
WO2008021954A2 (en) * 2006-08-09 2008-02-21 Biogen Idec Ma Inc. Method for distribution of a drug
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
TW200846363A (en) * 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
FR2919804B1 (fr) * 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
CN102272327B (zh) * 2008-11-07 2015-11-25 赛昆塔公司 通过序列分析监测状况的方法
AU2010210979B2 (en) 2009-02-05 2015-12-10 Biogen Ma Inc. Methods for the detection of JC polyoma virus
CN102326080B (zh) 2009-02-20 2015-08-05 加利福尼亚大学董事会 A+生物标志物的试验
EP4524571A3 (en) * 2010-01-11 2025-06-11 Biogen MA Inc. Assay for jc virus antibodies
KR102473834B1 (ko) 2011-05-31 2022-12-02 바이오젠 엠에이 인코포레이티드 Pml의 위험을 판단하는 방법
HK1216546A1 (zh) * 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法

Also Published As

Publication number Publication date
JP6663396B2 (ja) 2020-03-11
JP2020101556A (ja) 2020-07-02
SMT201900336T1 (it) 2019-07-11
EP3575792A1 (en) 2019-12-04
WO2012166971A2 (en) 2012-12-06
DK3575792T3 (da) 2023-02-27
JP6243838B2 (ja) 2017-12-06
EP2715352A4 (en) 2015-10-21
WO2012166971A8 (en) 2013-01-17
KR102039751B1 (ko) 2019-11-01
CN103635803A (zh) 2014-03-12
KR102473834B1 (ko) 2022-12-02
CY1121981T1 (el) 2020-10-14
EP4187248A1 (en) 2023-05-31
SI3575792T1 (sl) 2023-04-28
CA2836490A1 (en) 2012-12-06
WO2012166971A3 (en) 2013-03-07
FI3575792T3 (fi) 2023-03-17
JP2022023126A (ja) 2022-02-07
ES2939482T3 (es) 2023-04-24
LT3575792T (lt) 2023-03-10
KR20190122878A (ko) 2019-10-30
AU2012262122A1 (en) 2013-11-14
KR20210107138A (ko) 2021-08-31
AU2012262122B2 (en) 2016-12-08
LT2715352T (lt) 2019-06-10
US20250164486A1 (en) 2025-05-22
PT2715352T (pt) 2019-06-12
JP7353338B2 (ja) 2023-09-29
JP2023169307A (ja) 2023-11-29
PT3575792T (pt) 2023-02-28
EP3575792B1 (en) 2022-11-30
PL3575792T3 (pl) 2023-03-27
KR20140038440A (ko) 2014-03-28
SI2715352T1 (sl) 2019-06-28
EP2715352A2 (en) 2014-04-09
US20220011310A1 (en) 2022-01-13
HUE061244T2 (hu) 2023-06-28
US20190227064A1 (en) 2019-07-25
HRP20190860T1 (hr) 2019-06-28
PL2715352T3 (pl) 2019-09-30
DK2715352T3 (da) 2019-05-20
JP2017191111A (ja) 2017-10-19
ES2729945T3 (es) 2019-11-07
RS58967B1 (sr) 2019-08-30
US12105090B2 (en) 2024-10-01
JP7128221B2 (ja) 2022-08-30
KR102292563B1 (ko) 2021-08-24
EP2715352B1 (en) 2019-04-24
SMT202300060T1 (it) 2023-03-17
US12066442B2 (en) 2024-08-20
HUE043339T2 (hu) 2019-08-28
HRP20230186T1 (hr) 2023-03-31
JP2014518377A (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
JP7353338B2 (ja) Ｐｍｌの危険性を査定する方法
US12392784B2 (en) Method of assessing risk of PML
US20140322164A1 (en) Method of assessing risk of pml
HK40095348A (en) Method of assessing risk of pml
HK40018298B (en) Method of assessing risk of pml
HK40018298A (en) Method of assessing risk of pml
HK1196155B (en) Method of assessing risk of pml
HK1196155A (en) Method of assessing risk of pml